Press Room

2016 CPhI Worldwide

Start
Tuesday, October 04, 2016 - 00:00
End
Thursday, October 06, 2016 - 00:00
Location: Barcelona, Spain
Booth Number: 3F40

Hovione will be attending CPhI Worldwide 2016 in Barcelona, Spain. An event that is considered the world's leading European pharmaceutical exhibition, which brings together more than 36,000 pharma industry professionals from 150+ countries.

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

We look forward to meeting you at our booth # 3F40 in Barcelona.

 

HOVIONE SPEAKERS

 

Mon, Oct 3, 3:45 PM - Theatre One

CPhI's Pre-Connect Congress
Panel discussion: Special Drug Designations
Moderator: Cynthia Challener, Scientific Content Director, That’s Nice LLC

 

guy villax portrait photo Hovione

Guy Villax

Non-Executive Board Member

Degree in Accounting and Financial Management

Guy Villax has a degree in Management from the University College at Buckingham, UK.

Guy Villax was Hovione's Chief Executive from 1997 to 2022, having previously worked at Price Waterhouse in London and Hovione in Asia.

Guy holds leadership positions at industry associations and in Portuguese state organizations: Rx-360, Health Cluster Portugal, Portugal’s Business Roundtable; and the ANI (Portugal’s National Innovation Agency) and the CNCTI (National Council for Science, Technology and Innovation).

Wed, Oct 5, 3:30 PM - Theatre One

CPhI's Pharma Insight Briefings
Panel discussion: Beyond APIs: The Move into Formulation Services
Moderator: Rick Mullin, Senior Editor, American Chemical Society

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025